Login
Home
Charts
Search
Watchlist
Products

Fermenta Biotech Ltd

FERMENTA·BSE
471.40-0.61%Tue, 22 Sept '26

Fermenta Biotech Ltd

FERMENTA
BSE
471.40
-0.61%
|Tue, 22 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
1,387Cr
Close
Close Price
471.40
Industry
Industry
Pharma - API
PE
Price To Earnings
22.86
PS
Price To Sales
2.72
Revenue
Revenue
511Cr
Rev Gr TTM
Revenue Growth TTM
-3.15%
PAT Gr TTM
PAT Growth TTM
-44.02%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
5799977895156140136130137122122
Growth YoY
Revenue Growth YoY%
-42.080.4-7.4-5.267.058.143.774.437.0-12.2-13.1-10.6
Expenses
ExpensesCr
7174927776103103108104112102104
Operating Profit
Operating ProfitCr
-1425511953372827252018
OPM
OPM%
-24.525.45.51.019.834.026.420.720.518.216.414.8
Other Income
Other IncomeCr
-6353324951144
Interest Expense
Interest ExpenseCr
453344333333
Depreciation
DepreciationCr
666666665555
PBT
PBTCr
-29161-61245322824172615
Tax
TaxCr
068017-166585
PAT
PATCr
-2910-7-61138332218121910
Growth YoY
PAT Growth YoY%
-243.6126.5-35.0-368.3138.3279.3566.7464.362.1-68.3-44.2-55.9
NPM
NPM%
-51.110.1-7.3-7.611.724.223.815.813.88.815.37.8
EPS
EPS
-7.33.4-2.4-2.03.912.711.87.56.24.46.73.4
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
5799977895156140136130137122122
Growth YoY
Revenue Growth YoY%
-42.080.4-7.4-5.267.058.143.774.437.0-12.2-13.1-10.6
Expenses
ExpensesCr
7174927776103103108104112102104
Operating Profit
Operating ProfitCr
-1425511953372827252018
OPM
OPM%
-24.525.45.51.019.834.026.420.720.518.216.414.8
Other Income
Other IncomeCr
-6353324951144
Interest Expense
Interest ExpenseCr
453344333333
Depreciation
DepreciationCr
666666665555
PBT
PBTCr
-29161-61245322824172615
Tax
TaxCr
068017-166585
PAT
PATCr
-2910-7-61138332218121910
Growth YoY
PAT Growth YoY%
-243.6126.5-35.0-368.3138.3279.3566.7464.362.1-68.3-44.2-55.9
NPM
NPM%
-51.110.1-7.3-7.611.724.223.815.813.88.815.37.8
EPS
EPS
-7.33.4-2.4-2.03.912.711.87.56.24.46.73.4

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
153164302403292377399350336469525511
Growth
Revenue Growth%
8.26.984.233.6-27.729.35.6-12.2-4.139.911.9-3.1
Expenses
ExpensesCr
135152209255226296337332308360426421
Operating Profit
Operating ProfitCr
191293149658261182811010090
OPM
OPM%
12.37.330.836.922.421.615.45.08.223.419.017.6
Other Income
Other IncomeCr
339121288-204122925
Interest Expense
Interest ExpenseCr
61014211918172117141211
Depreciation
DepreciationCr
81012121520262825242221
PBT
PBTCr
7-676129435227-51-10839682
Tax
TaxCr
432111-1691221472624
PAT
PATCr
3-855118604315-53-24767058
Growth
PAT Growth%
184.4-403.4766.3115.0-49.5-28.5-64.6-452.854.8418.2-8.1-44.0
NPM
NPM%
1.8-5.018.129.220.411.33.8-15.2-7.216.313.411.4
EPS
EPS
-0.4-4.23.113.620.615.85.3-17.7-5.426.424.720.6
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
153164302403292377399350336469525511
Growth
Revenue Growth%
8.26.984.233.6-27.729.35.6-12.2-4.139.911.9-3.1
Expenses
ExpensesCr
135152209255226296337332308360426421
Operating Profit
Operating ProfitCr
191293149658261182811010090
OPM
OPM%
12.37.330.836.922.421.615.45.08.223.419.017.6
Other Income
Other IncomeCr
339121288-204122925
Interest Expense
Interest ExpenseCr
61014211918172117141211
Depreciation
DepreciationCr
81012121520262825242221
PBT
PBTCr
7-676129435227-51-10839682
Tax
TaxCr
432111-1691221472624
PAT
PATCr
3-855118604315-53-24767058
Growth
PAT Growth%
184.4-403.4766.3115.0-49.5-28.5-64.6-452.854.8418.2-8.1-44.0
NPM
NPM%
1.8-5.018.129.220.411.33.8-15.2-7.216.313.411.4
EPS
EPS
-0.4-4.23.113.620.615.85.3-17.7-5.426.424.720.6

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
222514141414141514
Reserves
ReservesCr
128142124246295346358301274348392
Current Liabilities
Current LiabilitiesCr
10886104156195209207209173212209
Non Current Liabilities
Non Current LiabilitiesCr
2449146145110117128115894439
Total Liabilities
Total LiabilitiesCr
288308387551614687707637548614648
Current Assets
Current AssetsCr
95104182296284310314253242335388
Non Current Assets
Non Current AssetsCr
194204204256330377393383306279260
Total Assets
Total AssetsCr
288308387551614687707637548614648
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
222514141414141514
Reserves
ReservesCr
128142124246295346358301274348392
Current Liabilities
Current LiabilitiesCr
10886104156195209207209173212209
Non Current Liabilities
Non Current LiabilitiesCr
2449146145110117128115894439
Total Liabilities
Total LiabilitiesCr
288308387551614687707637548614648
Current Assets
Current AssetsCr
95104182296284310314253242335388
Non Current Assets
Non Current AssetsCr
194204204256330377393383306279260
Total Assets
Total AssetsCr
288308387551614687707637548614648

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
7259903463431161054193
Investing Cash Flow
Investing Cash FlowCr
-157-101-97-44-42-26-55-160-43
Financing Cash Flow
Financing Cash FlowCr
10-128912-47-1-22-41-91-51-42
Net Cash Flow
Net Cash FlowCr
1-4476-5720-419-1-108
Free Cash Flow
Free Cash FlowCr
-23-174255-347676863863
CFO To PAT
CFO To PAT%
240.1-23.2108.176.657.9147.2288.4-218.5-438.853.5132.1
CFO To EBITDA
CFO To EBITDA%
34.616.063.760.752.876.770.7659.5382.937.393.0
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
7259903463431161054193
Investing Cash Flow
Investing Cash FlowCr
-157-101-97-44-42-26-55-160-43
Financing Cash Flow
Financing Cash FlowCr
10-128912-47-1-22-41-91-51-42
Net Cash Flow
Net Cash FlowCr
1-4476-5720-419-1-108
Free Cash Flow
Free Cash FlowCr
-23-174255-347676863863
CFO To PAT
CFO To PAT%
240.1-23.2108.176.657.9147.2288.4-218.5-438.853.5132.1
CFO To EBITDA
CFO To EBITDA%
34.616.063.760.752.876.770.7659.5382.937.393.0

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
1601766547556267376053154468059391,387
Price To Earnings
Price To Earnings
19.46.410.315.938.510.412.822.9
Price To Sales
Price To Sales
1.01.12.21.92.11.91.50.91.31.71.82.7
Price To Book
Price To Book
1.21.25.33.02.02.01.61.01.52.22.33.4
EV To EBITDA
EV To EBITDA
10.821.08.55.812.311.313.227.019.17.710.116.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
44.541.961.366.059.052.645.038.340.350.048.748.7
OPM
OPM%
12.37.330.836.922.421.615.45.08.223.419.017.6
NPM
NPM%
1.8-5.018.129.220.411.33.8-15.2-7.216.313.411.4
ROCE
ROCE%
7.42.030.733.512.111.77.2-5.71.720.420.720.7
ROE
ROE%
2.1-5.743.447.119.211.84.0-16.9-8.321.117.317.3
ROA
ROA%
0.9-2.714.221.49.76.22.1-8.3-4.412.410.810.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
1601766547556267376053154468059391,387
Price To Earnings
Price To Earnings
19.46.410.315.938.510.412.822.9
Price To Sales
Price To Sales
1.01.12.21.92.11.91.50.91.31.71.82.7
Price To Book
Price To Book
1.21.25.33.02.02.01.61.01.52.22.33.4
EV To EBITDA
EV To EBITDA
10.821.08.55.812.311.313.227.019.17.710.116.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
44.541.961.366.059.052.645.038.340.350.048.748.7
OPM
OPM%
12.37.330.836.922.421.615.45.08.223.419.017.6
NPM
NPM%
1.8-5.018.129.220.411.33.8-15.2-7.216.313.411.4
ROCE
ROCE%
7.42.030.733.512.111.77.2-5.71.720.420.720.7
ROE
ROE%
2.1-5.743.447.119.211.84.0-16.9-8.321.117.317.3
ROA
ROA%
0.9-2.714.221.49.76.22.1-8.3-4.412.410.810.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Fermenta Biotech is one of only three companies in the world that can make pharmaceutical-grade Vitamin D3 from start to finish, a position it has built over 55 years of manufacturing. The company began in 1951 as a toll manufacturer of pharmaceuticals, pivoted decisively into Vitamin D in 1967, and later consolidated its leadership by merging with DIL Limited in 2019, creating a single entity with a large asset base and a singular focus on nutritional wellness. Its recurring approach is to backward-integrate into the critical raw materials its rivals depend on-like cholesterol from wool grease-and then forward-integrate into the finished formats its customers actually use, from fortified rice kernels to spray-dried powders for supplements. # Business segments Two engines drive the business-a dominant Vitamin D3 and nutritional ingredients platform that supplies 350-plus customers across 60 countries, and a smaller but deeply connected biotechnology and green chemistry unit that makes the enzymes and specialty APIs the company has manufactured for decades. ## 1. Vitamin D3 and nutritional ingredients: where the company’s manufacturing moat lives **Fermenta is India’s only maker of Vitamin D3 and one of the world’s top three, with a supply chain that does not depend on China and a product range that stretches from the raw cholesterol starting material all the way to finished fortified foods.** - **Backward integration into the key raw material** - the company makes its own pharmaceutical-grade cholesterol (branded Fermsterol®) from wool grease, so it controls the starting material that other Vitamin D3 manufacturers must buy, insulating it from supply shocks and price swings. - **A multi-compendial, CEP-certified player** - Fermenta holds a certificate of suitability from the European Directorate for the Quality of Medicines, one of only three companies worldwide with this certification, which is a regulatory passport for selling into European pharmaceutical markets. - **A patented spray-dried format with limited competition** - its 100,000 IU/g spray-dried Vitamin D3 powder is protected by a process patent and provides superior stability for pharmaceutical formulations, giving it a differentiated product that competitors cannot easily replicate. - **A plant-based alternative for vegan markets** - Fermenta developed VITADEE™ Green, a Vitamin D3 derived from phytosterols rather than animal sources, and received FSSAI approval in July 2026 to sell it as an ingredient in health supplements and nutraceuticals, opening a new clean-label segment. ## 2. Integrated biotechnology and green chemistry: the enzyme engine **Fermenta has been making immobilised enzymes for nearly four decades, and its proprietary CAL B lipase and DILBEADS polymer platform let it replace harsh chemical reactions with cleaner, recyclable biocatalytic processes for pharmaceutical and oleochemical customers.** - **India’s first PGA manufacturer since 1986** - the company pioneered Penicillin G Amidase enzymes in India, which are used to make beta-lactam antibiotics like ampicillin and amoxicillin, and it continues to supply this established pharmaceutical biocatalyst market. - **A proprietary immobilisation platform** - Fermenta developed a library of polymer supports called DILBEADS that hold enzymes in place during reactions, making the enzymes reusable and giving customers a cost and sustainability advantage over single-use chemical catalysts. - **Green chemistry for a COVID-19 antiviral** - the company used its in-house CAL B lipase to patent an enzymatic synthesis route for Molnupiravir, an antiviral drug, achieving higher yields with lower solvent use than conventional chemical methods. - **Capacity expansion underway** - in December 2025, the board approved roughly Rs. 50 crore for a 75-kilolitre fermentation capacity expansion at Dahej, specifically for CAL-B Lipase and Penicillin G Acylase enzymes, financed through internal accruals and debt. # Group structure and partners **Fermenta operates through a network of wholly-owned subsidiaries in Germany, the US, and the UK that extend its manufacturing and distribution reach, while a newly carved-out subsidiary now houses the environmental solutions business.** - Fermenta Biotech GmbH in Hamburg collaborates with a toll manufacturer in Germany to produce Vitamin D3 500 feed-grade powder for the European animal nutrition market. - Fermenta USA LLC, formed after Fermenta Biotech USA LLC acquired a majority stake in AGD Nutrition LLC in 2020 and subsequently renamed it, distributes both animal feed ingredients and human dietary supplements across North America, giving the company direct access to its largest export market. - In September 2025, the environmental solutions division was transferred via slump sale to a newly incorporated wholly-owned subsidiary, Fermenta Environment Solutions Private Limited, for a consideration of Rs. 19 crore, allowing the parent to focus management attention on its core nutrition and biotechnology engines. - Promoter Krishna Datla holds just over 36% of the equity, and a shareholders’ agreement requires the promoter group to vote unanimously as directed by him, ensuring concentrated decision-making control.

Documents — Fermenta Biotech Ltd

  • Q4 FY2022 Earnings Call Transcript (Mar 2022, PDF): https://www.stockscans.in/document/mgnno8ufi9kgulp1haa2ua9t.pdf
  • Q3 FY2022 Earnings Call Transcript (Dec 2021, PDF): https://www.stockscans.in/document/d48tiqfg61d7mhm2gnfyn2as.pdf
  • Q2 FY2022 Earnings Call Transcript (Sep 2021, PDF): https://www.stockscans.in/document/y75qw4lzgllfzjkd8ry00up2.pdf
  • Q1 FY2022 Earnings Call Transcript (Jun 2021, PDF): https://www.stockscans.in/document/8hsnipyaqzwkag4e9eqqgjod.pdf
  • Q4 FY2021 Earnings Call Transcript (Mar 2021, PDF): https://www.stockscans.in/document/fjrwk9npixkb3lkdskxl7m81.pdf
  • Q3 FY2021 Earnings Call Transcript (Dec 2020, PDF): https://www.stockscans.in/document/o0gdwmr59a43davlqm5q95lg.pdf
  • Q2 FY2021 Earnings Call Transcript (Sep 2020, PDF): https://www.stockscans.in/document/4sh132g7dkrp3fypilc7sey7.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/ev4y9defs0rkz3iplw1m3a2p.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/1rrshwieexxm72vg5z3fsh2g.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/ez6bq0vm52x6da2y3a2gn8fk.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/rhqwr6y7ofm6fozan824luyt.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/vsuvyd2nyx4uncvmn84zh2sz.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/w73q3luczmb1i91sn9oazphu.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/am8c3fzagm2e4k2yko35xpid.pdf
  • Q4 FY2024 Quarterly Result (Mar 2024, PDF): https://www.stockscans.in/document/l5bz9kl2mt28xuzxkfqfe5d0.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/xp8hc226caarbbx4ke8otpwa.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/g4ed940pqg1ha5yhyetjr1kp.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/a9w05or47gqauz1r1y7yqzgw.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/q6ryke7b5mq9mtmzg75edfk0.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/ptbbd3glrajr0jr346iu05qn.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/a39r7sdzx9lqsdvgq4997h3q.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/ugype4tgpz8hr6dsn15vibjs.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/t4v2xj4ox6a7ilzjjk1r4t29.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/sfgxud9y8c051sat0yvydf8z.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/idn9xx3jj59be2va9ra0e325.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/gxbj2h6forgdi4botx9u5z9g.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/sf4jtkc73zokoa48o4et39pa.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/kqnw4s552g81y3l25x623y2q.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/fu8u76v9yaib9vxv7m58lqil.pdf